IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-28329-1.html
   My bibliography  Save this article

Development of a skin- and neuro-attenuated live vaccine for varicella

Author

Listed:
  • Wei Wang

    (Xiamen University)

  • Dequan Pan

    (Xiamen University)

  • Wenkun Fu

    (Xiamen University)

  • Xiangzhong Ye

    (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)

  • Jinle Han

    (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)

  • Lianwei Yang

    (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)

  • Jizong Jia

    (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)

  • Jian Liu

    (Xiamen University)

  • Rui Zhu

    (Xiamen University)

  • Yali Zhang

    (Xiamen University)

  • Che Liu

    (Xiamen University)

  • Jianghui Ye

    (Xiamen University)

  • Anca Selariu

    (Rutgers University)

  • Yuqiong Que

    (Xiamen University)

  • Qinjian Zhao

    (Xiamen University)

  • Ting Wu

    (Xiamen University)

  • Yimin Li

    (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.)

  • Jun Zhang

    (Xiamen University)

  • Tong Cheng

    (Xiamen University)

  • Hua Zhu

    (Rutgers University)

  • Ningshao Xia

    (Xiamen University)

Abstract

Varicella caused by the primary infection of varicella-zoster virus (VZV) exerts a considerable disease burden globally. Current varicella vaccines consisting of the live-attenuated vOka strain of VZV are generally safe and effective. However, vOka retains full neurovirulence and can establish latency and reactivate to cause herpes zoster in vaccine recipients, raising safety concerns. Here, we rationally design a live-attenuated varicella vaccine candidate, v7D. This virus replicates like wild-type virus in MRC-5 fibroblasts and human PBMCs, the carrier for VZV dissemination, but is severely impaired for infection of human skin and neuronal cells. Meanwhile, v7D shows immunogenicity comparable to vOka both in vitro and in multiple small animal species. Finally, v7D is proven well-tolerated and immunogenic in nonhuman primates. Our preclinical data suggest that v7D is a promising candidate as a safer live varicella vaccine with reduced risk of vaccine-related complications, and could inform the design of other herpes virus vaccines.

Suggested Citation

  • Wei Wang & Dequan Pan & Wenkun Fu & Xiangzhong Ye & Jinle Han & Lianwei Yang & Jizong Jia & Jian Liu & Rui Zhu & Yali Zhang & Che Liu & Jianghui Ye & Anca Selariu & Yuqiong Que & Qinjian Zhao & Ting W, 2022. "Development of a skin- and neuro-attenuated live vaccine for varicella," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28329-1
    DOI: 10.1038/s41467-022-28329-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-28329-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-28329-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Daniel P. Depledge & Werner J. D. Ouwendijk & Tomohiko Sadaoka & Shirley E. Braspenning & Yasuko Mori & Randall J. Cohrs & Georges M. G. M. Verjans & Judith Breuer, 2018. "A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61," Nature Communications, Nature, vol. 9(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28329-1. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.